These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 18555904)

  • 41. Editorial: is thalidomide a good option for patients with refractory Crohn's disease?
    Rogler G
    Aliment Pharmacol Ther; 2015 Apr; 41(8):785-6. PubMed ID: 25781038
    [No Abstract]   [Full Text] [Related]  

  • 42. Oral SMAD7 antisense drug for Crohn's disease.
    Vermeire S
    N Engl J Med; 2015 Mar; 372(12):1166-7. PubMed ID: 25785975
    [No Abstract]   [Full Text] [Related]  

  • 43. [Good results: antisense-oligonucleotide Mongersen is in Crohn's disease].
    Moskaleva M
    Dtsch Med Wochenschr; 2015 May; 140(10):710-1. PubMed ID: 26171473
    [No Abstract]   [Full Text] [Related]  

  • 44. Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease.
    Kennedy BW
    N Engl J Med; 2015 Jun; 372(25):2461. PubMed ID: 26083214
    [No Abstract]   [Full Text] [Related]  

  • 45. Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease.
    Monteleone G; Pallone F
    N Engl J Med; 2015 Jun; 372(25):2461. PubMed ID: 26083213
    [No Abstract]   [Full Text] [Related]  

  • 46. In the Presence of Conceptual Heterogeneity, Results of Network Meta-analysis Comparing Therapies in Crohn's Disease Need to Be Interpreted With Caution.
    Bonovas S; Moja L; Danese S
    Gastroenterology; 2015 Jun; 148(7):1483-4. PubMed ID: 25935528
    [No Abstract]   [Full Text] [Related]  

  • 47. Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way?
    Danese S; Fiorino G; Peyrin-Biroulet L
    Gastroenterology; 2015 Oct; 149(4):1121-3. PubMed ID: 26319033
    [No Abstract]   [Full Text] [Related]  

  • 48. Therapy: Oral SMAD7 antisense oligonucleotide proves effective for Crohn's disease.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2015 May; 12(5):251. PubMed ID: 25824998
    [No Abstract]   [Full Text] [Related]  

  • 49. Immunomodulation of Crohn's Disease.
    van Deventer SJ
    Curr Dir Autoimmun; 2000; 2():150-66. PubMed ID: 11791454
    [No Abstract]   [Full Text] [Related]  

  • 50. [Efficacy and Safety of an Oral SMAD7 Antisense Drug for Active Crohn's Disease].
    Seo GS
    Korean J Gastroenterol; 2015 Jun; 65(6):384-5. PubMed ID: 26288865
    [No Abstract]   [Full Text] [Related]  

  • 51. Editorial: mongersen in Crohn's disease--a new contribution to the beginning of a long-awaited therapeutic revolution?
    Kirchgesner J; Sokol H
    Aliment Pharmacol Ther; 2016 Apr; 43(7):838-9. PubMed ID: 26932411
    [No Abstract]   [Full Text] [Related]  

  • 52. Combined restitutive therapy for treatment of immunosuppressive refractory Crohn disease.
    Goldsmith JR; Kelly M; Freeman KB; Duro D
    J Pediatr Gastroenterol Nutr; 2015 Apr; 60(4):e31-4. PubMed ID: 24121152
    [No Abstract]   [Full Text] [Related]  

  • 53. Editorial: combination immunosuppressive therapy to treat Crohn's disease - ready for all age groups?
    Murray CDR
    Aliment Pharmacol Ther; 2019 Jun; 49(12):1528. PubMed ID: 31134656
    [No Abstract]   [Full Text] [Related]  

  • 54. Editorial: combination immunosuppressive therapy to treat Crohn's disease - ready for all age groups? Authors' reply.
    Singh S; Jairath V; Lw S; G Z; R K; Ps D; Wj S; Bg F
    Aliment Pharmacol Ther; 2019 Jun; 49(12):1529. PubMed ID: 31134649
    [No Abstract]   [Full Text] [Related]  

  • 55. More on lymphoproliferative disorders associated with crohn disease treatments.
    Griffiths AM
    J Pediatr Gastroenterol Nutr; 2013 Aug; 57(2):131-2. PubMed ID: 23676444
    [No Abstract]   [Full Text] [Related]  

  • 56. Reply: To PMID 25448924.
    Hazlewood GS; Rezaie A; Kaplan GG
    Gastroenterology; 2015 Jun; 148(7):1484. PubMed ID: 25935530
    [No Abstract]   [Full Text] [Related]  

  • 57. Reply: To PMID 25785968.
    Monteleone G; Pallone F
    Gastroenterology; 2015 Oct; 149(4):1123. PubMed ID: 26319031
    [No Abstract]   [Full Text] [Related]  

  • 58. Early Combined Immunosuppression in Crohn's Disease: Acting Rather Than REACTing.
    Peyrin-Biroulet L; Danese S
    Gastroenterology; 2016 Apr; 150(4):1040-1. PubMed ID: 26922865
    [No Abstract]   [Full Text] [Related]  

  • 59. [Not Available].
    Zink N
    MMW Fortschr Med; 2022 Sep; 164(15):21. PubMed ID: 36064902
    [No Abstract]   [Full Text] [Related]  

  • 60. Early combined immunosuppression in Crohn's disease.
    Herfarth H; Isaacs K
    Lancet; 2008 Jun; 371(9629):1995-6; author reply 1996-7. PubMed ID: 18555904
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.